AbbVie's menstrual migraine treatment meets late-stage study goal
- Posted on September 10, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
AbbVie's menstrual migraine treatment meets late-stage study goal
Sept 10 (Reuters) - AbbVie said on Thursday its migraine treatment had in a late-stage study reduced the migraine days associated with the menstrual period. The drug, chemically known as atogepant, is approved under brand name Qulipta in the U.S. as a preventive treatment for migraine in adults. The drug met the main goal of showing a greater reduction than placebo in migraine days during the
